Our goal is to build a commercial footprint that will deliver Idorsia’s deep pipeline of products from its R&D engine to the UK market – with the potential to change the lives of many patients.
Headquartered in Switzerland, Idorsia Ltd was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.
Strategy
We have identified five key strategic priorities to ensure the company’s success over the first five years.
Responsibilities
Idorsia’s corporate responsibility efforts encompass employee development and diversity, governance and ethics, as well as the organization’s economic, environmental, and social performance.
People
It’s the Idorsia team’s passion for science that will translate our objectives into value creation for all our stakeholders.
Research & Development
Idorsia aims to deliver new products with the potential to significantly change the treatment options in their target diseases.